Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 146

1.

Characterization of cyclic Cushing's disease using late night salivary cortisol testing.

Jahandideh D, Swearingen B, Nachtigall LB, Klibanski A, Biller BMK, Tritos NA.

Clin Endocrinol (Oxf). 2018 Jun 6. doi: 10.1111/cen.13758. [Epub ahead of print]

PMID:
29873834
2.

Macimorelin as a Diagnostic Test for Adult GH Deficiency.

Garcia JM, Biller BMK, Korbonits M, Popovic V, Luger A, Strasburger CJ, Chanson P, Medic-Stojanoska M, Schopohl J, Zakrzewska A, Pekic S, Bolanowski M, Swerdloff R, Wang C, Blevins T, Marcelli M, Ammer N, Sachse R, Yuen KCJ.

J Clin Endocrinol Metab. 2018 Aug 1;103(8):3083-3093. doi: 10.1210/jc.2018-00665.

PMID:
29860473
3.

Medical Therapy for Cushing's Syndrome in the Twenty-first Century.

Tritos NA, Biller BMK.

Endocrinol Metab Clin North Am. 2018 Jun;47(2):427-440. doi: 10.1016/j.ecl.2018.01.006. Epub 2018 Apr 9. Review.

PMID:
29754642
4.

The current state of long-acting growth hormone preparations for growth hormone therapy.

Yuen KCJ, Miller BS, Biller BMK.

Curr Opin Endocrinol Diabetes Obes. 2018 Aug;25(4):267-273. doi: 10.1097/MED.0000000000000416.

PMID:
29746309
5.

Growth Hormone Research Society perspective on biomarkers of GH action in children and adults.

Johannsson G, Bidlingmaier M, Biller BMK, Boguszewski M, Casanueva FF, Chanson P, Clayton PE, Choong CS, Clemmons D, Dattani M, Frystyk J, Ho K, Hoffman AR, Horikawa R, Juul A, Kopchick JJ, Luo X, Neggers S, Netchine I, Olsson DS, Radovick S, Rosenfeld R, Ross RJ, Schilbach K, Solberg P, Strasburger C, Trainer P, Yuen KCJ, Wickstrom K, Jorgensen JOL; Growth Hormone Research Society.

Endocr Connect. 2018 Mar;7(3):R126-R134. doi: 10.1530/EC-18-0047. Epub 2018 Feb 26. Review.

6.

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.

Strasburger CJ, Mattsson A, Wilton P, Aydin F, Hey-Hadavi J, Biller BMK.

Eur J Endocrinol. 2018 Apr;178(4):321-329. doi: 10.1530/EJE-17-0996. Epub 2018 Jan 25.

7.

Health Care Burden in Patients With Adrenal Insufficiency.

Gunnarsson C, Ryan MP, Marelli C, Baker ER, Stewart PM, Johannsson G, Biller BMK.

J Endocr Soc. 2017 Apr 12;1(5):512-523. doi: 10.1210/js.2016-1064. eCollection 2017 May 1.

8.

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.

Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK, Newell-Price J; Pasireotide G2304 Study Group.

Lancet Diabetes Endocrinol. 2018 Jan;6(1):17-26. doi: 10.1016/S2213-8587(17)30326-1. Epub 2017 Oct 12. Erratum in: Lancet Diabetes Endocrinol. 2018 Jan;6(1):e1.

PMID:
29032078
9.

Bone microarchitecture and estimated bone strength in men with active acromegaly.

Silva PPB, Amlashi FG, Yu EW, Pulaski-Liebert KJ, Gerweck AV, Fazeli PK, Lawson E, Nachtigall LB, Biller BMK, Miller KK, Klibanski A, Bouxsein M, Tritos NA.

Eur J Endocrinol. 2017 Nov;177(5):409-420. doi: 10.1530/EJE-17-0468. Epub 2017 Aug 5.

PMID:
28780520
10.

BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.

Geer EB, Shafiq I, Gordon MB, Bonert V, Ayala A, Swerdloff RS, Katznelson L, Lalazar Y, Manuylova E, Pulaski-Liebert KJ, Carmichael JD, Hannoush Z, Surampudi V, Broder MS, Cherepanov D, Eagan M, Lee J, Said Q, Neary MP, Biller BMK.

Endocr Pract. 2017 Aug;23(8):962-970. doi: 10.4158/EP171787.OR. Epub 2017 Jun 14.

PMID:
28614003
11.

Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.

Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, Scaroni C, Ravichandran S, Kandra A, Biller BMK.

Endocrine. 2017 Jul;57(1):156-165. doi: 10.1007/s12020-017-1316-3. Epub 2017 Jun 9.

12.

Radiotherapy, Especially at Young Age, Increases the Risk for De Novo Brain Tumors in Patients Treated for Pituitary/Sellar Lesions.

Burman P, van Beek AP, Biller BM, Camacho-Hübner C, Mattsson AF.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):1051-1058. doi: 10.1210/jc.2016-3402.

PMID:
28359095
13.

Is GH dosing optimal in female patients with adult-onset GH deficiency? An analysis from the NordiNet® International Outcome Study.

Höybye C, Weber MM, Pournara E, Tønnes Pedersen B, Biller BMK.

Clin Endocrinol (Oxf). 2017 Jun;86(6):798-805. doi: 10.1111/cen.13330. Epub 2017 Apr 19.

PMID:
28306165
14.

Follow-up intervals in patients with Cushing's disease: recommendations from a panel of experienced pituitary clinicians.

Geer EB, Ayala A, Bonert V, Carmichael JD, Gordon MB, Katznelson L, Manuylova E, Shafiq I, Surampudi V, Swerdloff RS, Broder MS, Cherepanov D, Eagan M, Lee J, Said Q, Neary MP, Biller BMK.

Pituitary. 2017 Aug;20(4):422-429. doi: 10.1007/s11102-017-0801-2.

PMID:
28275992
15.

Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis.

Tritos NA, Chanson P, Jimenez C, King D, Jönsson PJ, Klibanski A, Biller BM.

Eur J Endocrinol. 2017 Feb;176(2):213-220. Epub 2016 Nov 15.

16.

MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults.

Strasburger CJ, Vanuga P, Payer J, Pfeifer M, Popovic V, Bajnok L, Góth M, Olšovská V, Trejbalová L, Vadasz J, Fima E, Koren R, Amitzi L, Bidlingmaier M, Hershkovitz O, Hart G, Biller BM.

Eur J Endocrinol. 2017 Mar;176(3):283-294. doi: 10.1530/EJE-16-0748. Epub 2016 Dec 8.

17.

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.

Findling JW, Fleseriu M, Newell-Price J, Petersenn S, Pivonello R, Kandra A, Pedroncelli AM, Biller BM.

Endocrine. 2016 Nov;54(2):516-523. Epub 2016 May 21.

18.

The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the NordiNet® International Outcome Study.

Weber MM, Biller BM, Pedersen BT, Pournara E, Christiansen JS, Höybye C.

Clin Endocrinol (Oxf). 2017 Feb;86(2):192-198. doi: 10.1111/cen.13256. Epub 2016 Nov 21.

PMID:
27736009
19.

Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.

Tritos NA, Biller BM.

Pituitary. 2017 Feb;20(1):129-135. doi: 10.1007/s11102-016-0753-y. Review.

PMID:
27631335
20.

Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency.

Stewart PM, Biller BM, Marelli C, Gunnarsson C, Ryan MP, Johannsson G.

J Clin Endocrinol Metab. 2016 Dec;101(12):4843-4850. Epub 2016 Sep 13.

PMID:
27623069

Supplemental Content

Loading ...
Support Center